T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-12: Form 8-K; Period of report 2018-12-06; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2018-11-06: Form 8-K; Period of report 2018-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-09-07: Form 8-K; Period of report 2018-08-31; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2018-08-07: Form 8-K; Period of report 2018-08-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-12 | 8-K | 2018-12-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d516270d8k.htm |
| 2018-11-06 | 8-K | 2018-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2018, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2018 and held a conference call to discuss those results. | d640451d8k.htm |
| 2018-09-07 | 8-K | 2018-08-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d619158d8k.htm |
| 2018-08-07 | 8-K | 2018-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2018, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2018 and held a conference call to discuss those results. | d562249d8k.htm |
| 2018-06-13 | 8-K | 2018-06-08 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On June 8, 2018, the Audit Committee (the “Committee”) of the Board of Directors of T2 Biosystems, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, effective immediately. | d581474d8k.htm |
| 2018-06-12 | 8-K | 2018-06-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 (a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the “Company”) occurred on June 8, 2018. | d601120d8k.htm |
| 2018-06-04 | 8-K | 2018-05-29 | 2.02 Results of Operations and Financial Condition | 2.02 On May 29, 2018, T2 Biosystems, Inc. (the “Company”) held a conference call to discuss financial guidance for the remainder of fiscal year 2018. | d595937d8k.htm |
| 2018-06-04 | 8-K | 2018-05-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 On May 30, 2018, T2 Biosystems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 6,100,000 shares of the Company’s common stock to the Underwriters (the “Offering”). | d775850d8k.htm |
| 2018-05-30 | 8-K | 2018-05-29 | 8.01 Other Events | 8.01 On May 29, 2018, T2 Biosystems, Inc. issued a press release announcing that it received market clearance from the U.S. Food and Drug Administration (FDA) for the T2Bacteria® Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. | d585909d8k.htm |
| 2018-05-17 | 8-K | 2018-05-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d590870d8k.htm |
| 2018-05-11 | 8-K | 2018-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2018, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2018 and held a conference call to discuss those results. | d582997d8k.htm |
| 2018-03-09 | 8-K | 2018-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2018, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and fiscal year ended December 31, 2017 and held a conference call to discuss those results. | d534806d8k.htm |
| 2018-03-09 | 8-K | 2018-03-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 6, 2018, Joanne Spadoro notified T2 Biosystems, Inc. (the “Company”) of her resignation from her position as the Company’s Chief Operations Officer. | d463544d8k.htm |
| 2018-03-07 | 8-K | 2018-03-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 1, 2018, the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company”) adopted the T2 Biosystems, Inc. Inducement Award Plan (the “Inducement Award Plan”). | d531147d8k.htm |
| 2018-02-05 | 8-K | 2018-01-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On January 30, 2018, Darlene Deptula-Hicks notified T2 Biosystems, Inc. (the “Company”) of her resignation from her position as the Company’s Chief Financial Officer effective immediately. | d498860d8k.htm |
| 2018-01-08 | 8-K | 2018-01-04 | 2.02 Results of Operations and Financial Condition | 2.02 On January 4, 2018 the Company announced certain preliminary results for the quarter ended December 31, 2017. | d509309d8k.htm |